ProMIS Neurosciences Inc. (PMN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ProMIS Neurosciences Inc. stock (PMN) is currently trading at $17.43. ProMIS Neurosciences Inc. PS ratio (Price-to-Sales) is 5168.19. Analyst consensus price target for PMN is $34.36. WallStSmart rates PMN as Sell.
- PMN PE ratio analysis and historical PE chart
- PMN PS ratio (Price-to-Sales) history and trend
- PMN intrinsic value — DCF, Graham Number, EPV models
- PMN stock price prediction 2025 2026 2027 2028 2029 2030
- PMN fair value vs current price
- PMN insider transactions and insider buying
- Is PMN undervalued or overvalued?
- ProMIS Neurosciences Inc. financial analysis — revenue, earnings, cash flow
- PMN Piotroski F-Score and Altman Z-Score
- PMN analyst price target and Smart Rating
ProMIS Neurosciences Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
ProMIS Neurosciences Inc. (PMN) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
ProMIS Neurosciences Inc. (PMN) Key Strengths (0)
Supporting Valuation Data
ProMIS Neurosciences Inc. (PMN) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 5168.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.2x book value
Moderate institutional interest at 32.62%
Supporting Valuation Data
ProMIS Neurosciences Inc. (PMN) Detailed Analysis Report
Overall Assessment
This company scores 14/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 0 register as strengths (avg 0/10) while 5 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (5168.19), Price/Book (4.24) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -355.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -355.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PMN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PMN's Price-to-Sales ratio of 5168.19x trades 1175% above its historical average of 405.43x (97th percentile), historically expensive. The current valuation is 2% below its historical high of 5252.72x set in Feb 2026, and 1845682% above its historical low of 0.28x in Mar 2015. Over the past 12 months, the PS ratio has expanded from ~185.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for ProMIS Neurosciences Inc. (PMN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ProMIS Neurosciences Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 7,560 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 129595% of revenue (10M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ProMIS Neurosciences Inc..
Bottom Line
ProMIS Neurosciences Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ProMIS Neurosciences Inc.(PMN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ProMIS Neurosciences Inc. is an innovative biotechnology company focused on developing transformative therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the firm identifies and targets misfolded proteins linked to these debilitating conditions, delivering the potential for groundbreaking treatments with enhanced safety profiles. With a diverse pipeline of drug candidates progressing through various stages of development, ProMIS stands at the forefront of neurotherapeutic advancements, poised to address significant unmet medical needs and exert a meaningful impact within the biopharmaceutical landscape.